Nilotinib in locally advanced pigmented villonodular synovitis: challenges of a new targeted therapy
- 1 May 2018
- journal article
- editorial
- Published by Elsevier in The Lancet Oncology
- Vol. 19 (5) , 584-586
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trialThe Lancet Oncology, 2018
- Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)Orthopaedics & Traumatology: Surgery & Research, 2017
- CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 studyThe Lancet Oncology, 2015
- Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitorsEuropean Journal of Cancer, 2015
- Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitisCancer, 2011
- A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cellsProceedings of the National Academy of Sciences, 2006
- Pigmented villonodular synovitis of the knee. The results of total arthroscopic synovectomy, partial, arthroscopic synovectomy, and arthroscopic local excision.Journal of Bone and Joint Surgery, 1992